RxDoctor Payments Data

Jennifer Kekis

Psychiatric/Mental Health · Albany, NYNPI 1982246310

Payments from drug & device makers

$2,604in general payments, 2019–2025

Across 66 payments — averaging $39.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$644
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$510
  • Otsuka America Pharmaceutical, Inc.$505
  • Axsome Therapeutics, Inc.$238
  • Sunovion Pharmaceuticals Inc.$207
  • Johnson & Johnson$134
  • plus $366 from 6 others

What the payments were for

  • Food & beverage$2,604100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,604 in reported general payments places this provider in the 80th percentile of 2,385 psychiatric/mental health providers in New York.

See all psychiatric/mental health providers in New York

Medicare billing

Part B allowed, 2024
$7,138
Medicare patients
12
Services billed
81

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate22$82,099
Aripiprazole84$7,989
Tegretol XrCarbamazepine12$5,274
Olanzapine35$1,031
Alprazolam ErAlprazolam17$942
Paliperidone ErPaliperidone12$671
Bupropion XlBupropion Hcl47$627
Quetiapine Fumarate31$606
Trazodone Hcl60$544
Clonazepam46$425
Mirtazapine40$423
Buspirone Hcl30$418
Escitalopram Oxalate62$373
Bupropion Hcl40$367
Divalproex Sodium15$339

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$134$82,09922 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,385 psychiatric/mental health providers in New York.

Other psychiatric/mental health in Albany

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →